Trial Profile
Ezetimibe versus rosuvastatin in patients with dyslipidaemias
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2011
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Rosuvastatin (Primary)
- Indications Dyslipidaemias
- Focus Pharmacodynamics
- 29 Apr 2011 New trial record
- 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.